Patient group
Kinder ab Geburt und Erwachsene mit schwerer Malaria (zur initialen Behandlung)
completed2024-11-01D series
Artesunat
schwere Malaria, ab Geburt
Open official case page ↗
- Brand
- Artesunate Amivas
- Manufacturer
- Amivas Ireland Ltd
G-BA action
final resolution
2025-04-17
Arzneimittel-Richtlinie/Anlage XII: Artesunat (schwere Malaria, ab Geburt)
Evidence-checked summary
The G-BA found non-quantifiable added benefit for Kinder ab Geburt und Erwachsene mit schwerer Malaria (zur initialen Behandlung). The G-BA issued a final resolution on 2025-04-17. The official page states that it took effect as follows: 17.04.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2025-03-10
27 parsed turns
Oral hearing: Artesunat (schwere Malaria, ab Geburt)
Official Wortprotokoll · 7 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
Distinct actions and documents
2025-04-17
final resolution
Arzneimittel-Richtlinie/Anlage XII: Artesunat (schwere Malaria, ab Geburt)
The G-BA found non-quantifiable added benefit for Kinder ab Geburt und Erwachsene mit schwerer Malaria (zur initialen Behandlung). The G-BA issued a final resolution on 2025-04-17. The official page states that it took effect as follows: 17.04.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources